GID BIO INC.

GID Bio is a clinical-stage regenerative medicine company developing autologous stromal vascular fraction (SVF) cell therapy for osteoarthritis treatment. The company has completed a Phase 3 FDA IDE clinical trial for knee osteoarthritis, demonstrating 73% reduction in pain and 115% improvement in function versus sham control with no adverse safety events reported. GID Bio is preparing a PMA (Premarket Approval) submission to the FDA. The therapy uses the patient's own cells (autologous approach) rather than allogeneic stem cells, positioning it within the cell therapy and regenerative medicine space. Leadership includes founders with orthopedic and plastic surgery expertise (Adam Katz, MD; J. William Futrell, MD; G. Patrick Maxwell, MD; Ramón Llull, MD, PhD) and experienced board members. The company is pre-commercial, currently advancing through the FDA approval pathway with intent to commercialize following regulatory clearance.